What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Colorectal cancer, Oxaliplatin, Fluorouracil and Gastroenterology are his primary areas of study.
His Internal medicine research includes elements of Surgery and Oncology.
His research integrates issues of Bevacizumab and Adjuvant in his study of Colorectal cancer.
His research in Oxaliplatin tackles topics such as Folinic acid which are related to areas like FOLFOXIRI, FOLFIRI Regimen, XELIRI and Febrile neutropenia.
His work in Fluorouracil covers topics such as FOLFOX which are related to areas like Tolerability.
His work deals with themes such as Progressive disease, Progression-free survival, Survival rate, Neutropenia and Retrospective cohort study, which intersect with Gastroenterology.
His most cited work include:
- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer (2651 citations)
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study (2448 citations)
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial (1451 citations)
What are the main themes of his work throughout his whole career to date?
Thierry André mainly focuses on Internal medicine, Oncology, Colorectal cancer, Oxaliplatin and Chemotherapy.
Thierry André has researched Internal medicine in several fields, including Gastroenterology and Surgery.
When carried out as part of a general Oncology research project, his work on Adjuvant is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
His Colorectal cancer study which covers Bevacizumab that intersects with Erlotinib.
His Oxaliplatin research is multidisciplinary, incorporating perspectives in Phases of clinical research, Capecitabine, Standard treatment, Folinic acid and Adjuvant therapy.
His studies in Chemotherapy integrate themes in fields like Adenocarcinoma and Hazard ratio.
He most often published in these fields:
- Internal medicine (76.05%)
- Oncology (57.49%)
- Colorectal cancer (53.09%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (76.05%)
- Oncology (57.49%)
- Colorectal cancer (53.09%)
In recent papers he was focusing on the following fields of study:
Thierry André mostly deals with Internal medicine, Oncology, Colorectal cancer, Microsatellite instability and Oxaliplatin.
His Internal medicine study frequently links to adjacent areas such as Gastroenterology.
In Oncology, Thierry André works on issues like Prospective cohort study, which are connected to Retrospective cohort study and Clinical endpoint.
His Colorectal cancer study also includes fields such as
- Post-hoc analysis together with Carcinoembryonic antigen,
- Radiology and KRAS most often made with reference to Proportional hazards model.
His Oxaliplatin study combines topics in areas such as Irinotecan, Capecitabine, Adjuvant therapy and Hazard ratio.
His studies deal with areas such as Regimen and FOLFIRI as well as FOLFOX.
Between 2018 and 2021, his most popular works were:
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. (147 citations)
- 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. (136 citations)
- Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. (76 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Oncology, Colorectal cancer, Microsatellite instability and Oxaliplatin.
Internal medicine and Gastroenterology are commonly linked in his work.
The various areas that Thierry André examines in his Oncology study include Stage and Blockade.
His work carried out in the field of Colorectal cancer brings together such families of science as Immune checkpoint, Cancer research, Clinical trial, Phases of clinical research and Confidence interval.
His research in Microsatellite instability intersects with topics in Pembrolizumab and DNA mismatch repair.
His Oxaliplatin research is multidisciplinary, incorporating elements of Irinotecan, Chemotherapy regimen, Cohort study and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
